Free tool
FAERS Monitor: Yonsa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210308 or its brand name (Yonsa, Abiraterone Acetate). Reports on generic versions are filed under their own applications.
Reports
6,863
Serious
5,670
83% of reports
Hospitalization
2,967
Death reported
1,274
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death751
- fatigue513
- hot flush294
- asthenia279
- anaemia247
- hypokalaemia240
- diarrhoea217
- prostatic specific antigen increased217
- disease progression215
- drug ineffective213
- prostate cancer210
- pneumonia208
- fall206
- hypertension206
- therapy interrupted204
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 13 |
| 2011 | 119 |
| 2012 | 213 |
| 2013 | 123 |
| 2014 | 214 |
| 2015 | 199 |
| 2016 | 161 |
| 2017 | 203 |
| 2018 | 267 |
| 2019 | 514 |
| 2020 | 728 |
| 2021 | 541 |
| 2022 | 788 |
| 2023 | 834 |
| 2024 | 579 |
| 2025 | 852 |
| 2026 | 515 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,296 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| prostatic specific antigen increasedSignal | 217 | 49.0 | 43.0 | 10,008 |
| hypokalaemiaSignal | 240 | 16.0 | 14.1 | 3,353 |
| hot flushSignal | 294 | 12.0 | 10.7 | 2,952 |
| therapy interruptedSignal | 204 | 8.8 | 7.7 | 1,397 |
| prostate cancerSignal | 210 | 8.0 | 7.0 | 1,285 |
| disease progressionSignal | 215 | 5.6 | 4.9 | 806 |
| anaemiaSignal | 247 | 4.0 | 3.5 | 551 |
| hypertensionSignal | 206 | 3.0 | 2.6 | 272 |
| deathSignal | 751 | 2.7 | 2.5 | 818 |
| astheniaSignal | 279 | 2.3 | 2.0 | 202 |
| fatigueSignal | 513 | 2.0 | 1.9 | 273 |
| pneumonia | 208 | 2.0 | 1.7 | 100 |
| fall | 206 | 1.9 | 1.7 | 88 |
| diarrhoea | 217 | 1.0 | 0.9 | 0 |
| drug ineffective | 213 | 0.5 | 0.4 | 116 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.